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To the Editor. 
While Idiopathic pulmonary fibrosis (IPF) remains the exemplar progressive fibrotic lung disease, 
there remains a cohort of non-IPF fibrotic lung diseases (fILD) which adopt a similar clinical 
behaviour to IPF despite therapy [1]. This phenotypically related group of conditions, where 
progression of disease is similar to that seen in IPF, have recently been described as Progressive 
Fibrotic Interstitial Lung diseases (PF-ILD) [2]. Historically treatments for these cases have been 
limited though given the phenotypic similarities many cases may have been given a multidisciplinary 
working diagnosis of IPF based on their disease behaviour [3]. The INBUILD trial broadened the 
scope of treatable fILD by demonstrating a significant benefit of Nintedanib in patients with fILD and 
progressive disease [4]. In response to this the European Commission (EC) approved an additional 
indication for Nintedanib in adults for the treatment of PF-ILD in July 2020. 
While research interest grows in the progressive phenotype and debates about the optimal 
diagnostic criteria continue the incidence of patients with PF-ILD potentially eligible for treatment 
according to the criteria laid out in the INBUILD trial remains unclear. Previous attempts to estimate 
the proportion of fILD who develop a progressive fibrotic phenotype have either used estimates 
based on the disease behaviour of individual conditions [5], interviews with experts [6] or analysis of 
insurance claims [7].  This has resulted in estimates ranging from 18 to 40% of all fILD that will 
develop progressive disease. With the anticipated approval of therapeutic interventions for this 
cohort of patients worldwide, including in the UK, there is an urgent need to refine these estimates 
in a real-world population to enable appropriate service provision. 
This retrospective, observational study therefore aimed to estimate the incidence of PF-ILD across 
England. Nine centres providing commissioned tertiary referral services for ILD were included. All 
new referrals seen for their first outpatient clinic appointment between 1st August 2017 and 31st 
January 2018 were assessed against the diagnostic criteria for PF-ILD laid out in the INBUILD trial [8] 
and in particular, the criteria for progression: relative decline in FVC % predicted ≥10%, or FVC 
decline ≥5% but <10%, combined with worsening respiratory symptoms, or FVC decline ≥5% but 
<10%, combined with radiological progression; or radiological progression with worsening 
respiratory symptoms. A full chart and imaging review was undertaken of all the subjects. 
Continuous variables are presented as means (± Standard Deviation [SD]), and categorical variables 
as proportions. Time-to-event curves were calculated using the Kaplan–Meier method and 
compared with the use of the log-rank test. 
A total of 2368 patients with ILD were assessed across the 9 centres. Six hundred and nineteen 
patients were diagnosed and managed as IPF and therefore excluded, leaving 1749 patients with 
fILD who were screened against the INBUILD criteria for progression, to identify cases of PF-ILD 
either at the first clinical review, or in the subsequent 2 years of follow up (Table 1). In the cohort of 
patients at risk of developing PF-ILD the INBUILD criteria were met in 14.5% (253/1749) of all new 
non-IPF fILD referrals despite standard therapy, with a range between these specialist ILD centres 
from 8.9% to 23.6% of total cases. The average time from referral to specialist centre to diagnosis of 
progressive phenotype was 311(±273) days and at the time of referral 20% of patients demonstrated 
progressive disease (66/253) despite standard therapy. All most all patients received at least one 
immunosuppressive agent, with the majority receiving either oral or intravenous corticosteroids 
(96%). A number of second line agents were employed with Mycophenolate (46%) the most 
commonly used. Five of the subjects with PF-ILD received antifibrotic therapy on compassionate 
grounds. 
The most common diagnoses associated with a PF-ILD phenotype were chronic hypersensitivity 
pneumonitis (84/253, 33.2%), unclassifiable ILD (44/253, 17.3%), connective tissue disease-
associated ILDs including rheumatoid arthritis-associated ILD (42/253, 16.6%) and non-specific 
Interstitial pneumonitis (36/253, 14.2%). In the PF-ILD cases, the mean age was 68 ±12.4 years and 
interestingly 53.4% of the cohort was female, as compared to the well-recognised male 
predominance seen in IPF. This is likely driven by the significant female predominance in both CHP 
and CTD which make up almost half of the PF-ILD cases.  
 
Patients with progressive disease had a significantly higher mortality compared to those with non-
progressive fILD (hazard ratio, 3.32; 95% confidence interval, 2.53–4.37; P=<2e-16). Indeed, the 
survival of patients with PF-ILD was no different to the subjects with IPF (hazard ratio, 1.06; 95% 
confidence interval, 0.84–1.35; P=0.6) (Figure 1). 
 
Figure 1. Kaplan-Meier curves comparing survival between patients with IPF, PF-ILD and non-
progressive fILD. Log-rank P test value is reported. 
Of the progression events the majority were driven by a measured drop in FVC, with more than half 
of patients (52.2%) experiencing a drop of ≥10%. A further quarter of patients (24.1%) were 
diagnosed with progressive disease on the basis of radiological and symptomatic progression alone 
without a spirometric deterioration. The remainder experienced a decline of FVC between 5 and 
10% with either radiological (15.8%) or symptomatic (7.9%) progression.  
The variations between centres and clinicians in diagnostic pathways, approaches to follow-up and 
definitions of progression has previously made it difficult to define and assess this cohort of patients. 
One of the strengths of our approach was the central collation and uniform application of the 
INBUILD inclusion criteria. However, this was done retrospectively and this is the main limitation of 
our study. While the INBUILD trial criteria are mostly objectively measurable phenomena, the 
definition of progressive symptoms may allow some biasing towards inclusion in those cases where 
spirometric progression was either not evidenced or not available, thus increasing the numbers of 
cases. Over a quarter of referrals received a final multidisciplinary team (MDT) diagnosis of IPF, and 
this is often pragmatic and based on their clinical disease behaviour, to allow access to antifibrotic 
therapy. However, a patient’s initial clinical and radiological features may have had more in keeping 
with a different ILD but with a PF-ILD phenotype. While all of the cases underwent local ILD 
multidisciplinary assessment, we did not undertake any central reassessment and therefore some 
cases of non-IPF PF-ILD may have been missed. Progression was only assessed at presentation and 
over a period of two years, as per the INBUILD screening criteria, however, we do know that 
progression may occur later during follow-up [9] and therefore some late progressors would not 
have been captured in this analysis. Our estimates therefore maybe if anything an underestimate 
but importantly they reflect current clinical practice, which we aimed to capture. 
This study represents a fair and balanced approach to assessing the incidence of objectively 
measurable and treatable PF-ILDs in the UK. A rate of 14.5% of new referrals with non-IPF ILD is less 
than that reported in previous studies however our methodology is likely to give a more accurate 
result than estimates based on extrapolation from general disease statistics, from physician-
reported estimates prone to significant biases, or insurance claim processes also substantially prone 
to bias. This information has implication for workforce planning and the funding of anti-fibrotic 
therapy in the UK and beyond. 
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